Copernicus Therapeutics Inc.

Nucleic Acid Nanoparticles for Treating Human Diseases

CopernicusLogo1Cutout3.jpgTubes.jpg4413SM2.jpg

SELECTED PRESS RELEASES



2013


A noninvasive avenue for Parkinson's disease gene therapy.

Read More...

 

Wipo Publishes Patent of Northeastern University and Copernicus Therapeutics for "Methods for Delivery to the Central Nervous System of Nucleic Acid Nanoparticles to Treat Central Nervous System Disorders"

Read More...



2011


Foundation Fighting Blindness invests $8.25 million in gene therapy research
Read More...



2009


Copernicus to Further Development of Non-Viral Gene Therapy for Parkinson’s Disease

Read More...



2008


Case Western Reserve University with Copernicus Therapeutics and Polgenix Receive $3.9 Million from the Ohio Biomedical Research Commercialization Program (BRCP)

Read More...



2007


Copernicus Receives Milestone Payment from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic Fibrosis.
Read More...



Copernicus Nanoparticle Technology Applied to siRNA.

Read More...


Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA.

Read More...


Copernicus to Receive Increased Support from Cystic Fibrosis Foundation Therapeutics to Further Development of its Non-Viral Gene Therapy for Cystic Fibrosis.

Read More...




2006



Copernicus Demonstrates Ability of its Non-Viral Delivery System to Efficiently Transfer Large Sizes of Nucleic Acids into Lung Cells.

Read More...










dsgn_764_lin.jpgdsgn_764_lin.jpgdsgn_764_lin.jpgdsgn_764_lin.jpgdsgn_764_lin.jpgdsgn_764_lin.jpgswirl8.jpg